Unit:
Faculty of MedicineLibrary of the School of Health Sciences
Dissertation committee:
Δέσποινα Ν. Περρέα, Ομότιμη Καθηγήτρια, Ιατρική Σχολή, ΕΚΠΑ, Επιβλέπουσα
Δημήτριος Χ. Ηλιόπουλος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κίμων Σ. Σταματελόπουλος, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Αθανάσιος Παπαβασιλείου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Κόντζογλου, Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Κωνσταντίνος Μακρυλάκης, Αναπληρωτής Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Στυλιανός Κύκαλος, Επίκουρος Καθηγητής, Ιατρική Σχολή, ΕΚΠΑ
Original Title:
Η επίδραση της Μαστίχας Χίου (Pistacia lentiscus var chia) σε πειραματικό μοντέλο αθηρωμάτωσης
Translated title:
The effect of Chios Mastic Gum (Pistacia lentiscus var chia) on an experimental model of atherosclerosis
Summary:
Aim
We sought to examine the hypothesis that Chios Mastic Gum (CMG) exerts peroxosime proliferator-activated receptor alpha (ppar-alpha) mediated hypolipidemic and hepatoprotective effects in an animal model of atherosclerosis.
Methods
30 adult male C57bl/6 mice and 30 adult male ppar-alpha knockout mice were randomly allocated into three groups per breed : Control group(n=10), High Fat group(HF)(n=10) and CMG group(n=10). Both HF and CMG groups received high fat diet for 12 weeks. CMG was given orally in a daily dose of 40 mg/kg BW for the same period. Body weight and serum biochemical parameters, as well as hemodynamic parameteres were determined at baseline, at 4, 8 and 12 weeks.The levels of proinflammatory cytokines were assessed and histological evaluation of liver lesions was performed.
Results
At the end of the study, the C57bl/6 CMG group presented significantly lower body weight (34 vs 30 g, p<0.01), total cholesterol (129.2 vs 148.1 mg/dl ,p<0.001) and LDL cholesterol levels(58 vs 82.6, p<0.001) compared with the C57bl/6 HF group. CMG administration resulted in an gradual 7.2% increase of HDL levels in C57bl/6 mice(p<0.05). After 12 weeks of CMG administration, C57bl/6 mice became normoglycemic compared with the HF group (177 vs 233.1 mg/dl, p<0.01). High fat induced hepatic steatosis was alleviated in the C57bl/6 group treated with CMG(NAS score 0.525 vs 0.975 in HF group , p<0.05). However, none of these differences were observed between ppar-a HF and ppar-a CMG groups. Finally, CMG inhibited the increase of the proinflammatory cytokines CRP, IL1a, CXCL10, MCP2, WVF, CXCL2 in the serum of mice only C57bl/6 (p<0.05 each).
Conclusion
CMG possesses anti-atherogenic and hepatoprotective effects that may be mediated through a ppar-a agonistic mechanism. CMG can be considered as a valuable food supplement in patients with metabolic disease.
Main subject category:
Health Sciences
Keywords:
Chios Mastic Gum, Atherosclerosis, Metabolic syndrome, Lipids, Inflammation, Non-alcoholic fatty liver disease, PPAR-α receptors, Mice
Number of references:
178
File:
File access is restricted only to the intranet of UoA.
Tzani Aspasia PhD.pdf
143 MB
File access is restricted only to the intranet of UoA.
